NasdaqCM - Delayed Quote USD

Universe Pharmaceuticals INC (UPC)

2.1800 -0.1200 (-5.22%)
At close: 4:00 PM EDT
2.1800 0.00 (0.00%)
After hours: 4:12 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
9/30/2023
9/30/2022
9/30/2021
9/30/2020
Total Revenue
32,308.7350
32,308.7350
40,143.1510
47,982.0310
30,703.9600
Cost of Revenue
21,993.6010
21,993.6010
18,251.8150
22,655.8540
16,610.1400
Gross Profit
10,315.1340
10,315.1340
21,891.3360
25,326.1770
14,093.8200
Operating Expense
14,281.2350
14,281.2350
28,910.7810
11,966.2120
3,743.9940
Operating Income
-3,966.1010
-3,966.1010
-7,019.4450
13,359.9650
10,349.8260
Net Non Operating Interest Income Expense
-156.7880
-156.7880
-162.4000
-101.6040
-123.7600
Other Income Expense
273.3150
273.3150
-802.3020
420.1170
-125.6330
Pretax Income
-3,849.5740
-3,849.5740
-7,984.1470
13,678.4780
10,100.4330
Tax Provision
2,313.4870
2,313.4870
752.4190
2,358.5260
2,542.2110
Net Income Common Stockholders
-6,163.0610
-6,163.0610
-8,736.5660
11,319.9520
7,558.2220
Diluted NI Available to Com Stockholders
-6,163.0610
-6,163.0610
-8,736.5660
11,319.9520
7,558.2220
Basic EPS
-1.70
--
-2.41
3.58
2.16
Diluted EPS
-1.70
--
-2.41
3.58
2.16
Basic Average Shares
3,625.0000
--
3,625.0000
3,163.4700
3,500.0000
Diluted Average Shares
3,625.0000
--
3,625.0000
3,163.4700
3,500.0000
Total Operating Income as Reported
-3,526.7740
-3,526.7740
-7,438.7980
13,590.1400
10,251.7250
Total Expenses
36,274.8360
36,274.8360
47,162.5960
34,622.0660
20,354.1340
Net Income from Continuing & Discontinued Operation
-6,163.0610
-6,163.0610
-8,736.5660
11,319.9520
7,558.2220
Normalized Income
-6,521.4538
-6,521.4538
-8,069.1935
10,930.5508
7,631.6015
Interest Expense
156.7880
156.7880
162.4000
101.6040
123.7600
Net Interest Income
-156.7880
-156.7880
-162.4000
-101.6040
-123.7600
EBIT
-3,692.7860
-3,692.7860
-7,821.7470
13,780.0820
10,224.1930
EBITDA
-3,184.0010
-3,184.0010
-7,287.7980
14,226.9600
10,634.2720
Reconciled Cost of Revenue
21,680.2670
21,680.2670
17,903.0350
22,381.4290
16,388.7310
Reconciled Depreciation
508.7850
508.7850
533.9490
446.8780
410.0790
Net Income from Continuing Operation Net Minority Interest
-6,163.0610
-6,163.0610
-8,736.5660
11,319.9520
7,558.2220
Total Unusual Items Excluding Goodwill
477.8570
477.8570
-889.8300
469.7240
-98.1010
Total Unusual Items
477.8570
477.8570
-889.8300
469.7240
-98.1010
Normalized EBITDA
-3,661.8580
-3,661.8580
-6,397.9680
13,757.2360
10,732.3730
Tax Rate for Calcs
0.0003
0.0003
0.0003
0.0002
0.0003
Tax Effect of Unusual Items
119.4643
119.4643
-222.4575
80.3228
-24.7215
9/30/2020 - 3/23/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

RGC Regencell Bioscience Holdings Limited
5.35
-5.31%
 
CANQF CanaQuest Medical Corp.
0.1399
0.00%
 
ARYX ARYx Therapeutics, Inc.
0.0000
0.00%
 
CNADF CanadaBis Capital Inc.
0.0650
0.00%
 
GFI.NZ Greenfern Industries Limited
0.0340
0.00%
 
CNGGF Cann Group Limited
0.0275
0.00%
 
MILFF 1CM Inc.
0.7246
0.00%
 
AOLS Aeolus Pharmaceuticals, Inc.
0.0000
0.00%
 
SKYI Sky Century Investment, Inc.
0.0035
0.00%
 
XTXXF Adastra Holdings Ltd.
0.1850
0.00%